Smoking CessationNCT07079306
ChatGPT-Supported Text Messaging Program for Smoking Cessation
A study testing BeFree+Bot and BeFree in people with Smoking Cessation, run by George Washington University at 1 site in United States.
Trial summary
The current research proposal aims to explore how a purpose driven LLM ChatGPT chatbot, BeFreeBot, might enhance an evidence-based text messaging smoking cessation program, BeFree. The research will consist of a formative evaluation comparing quitting related outcomes among users of BeFree+Bot and BeFree. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Smoking Cessation
- What is being tested?
- BeFree+Bot and BeFree
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 180 participants
- Where
- 1 siteUnited States
- Study dates
- Oct 2026to 30 Oct 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- lives in the US
- smoked a cigarette within the last 7 days
- has a mobile phone
- willing to receive text messages about the health effects of smoking on their mobile phone for 30 days
- willing to set a quit date in the next 7 days
- not pregnant
Who cannot join
- none
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Prolific
Washington D.C., District of Columbia, 20052
About this study
Official title: Engagement and Satisfaction With a ChatGPT-Supported Text Messaging Program for Smoking Cessation
The current research proposal aims to explore how a purpose driven LLM ChatGPT chatbot, BeFreeBot, might enhance an evidence-based text messaging smoking cessation program, BeFree. The research will consist of a formative evaluation comparing quitting related outcomes among users of BeFree+Bot and BeFree.
- Conditions
- Smoking Cessation
- Being tested
- BeFree+Bot, BeFree
- Keywords
- smoking cessation, ai, text messaging
- Medical subject headings
- Smoking Cessation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BeFree+BotBehavioural
Text messaging program called BeFree and access to BBot, ChatGPT chatbot
BeFreeBehavioural
Text messaging program called BeFree
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Text messages about quitting smoking and access to specialized ChatGPT chatbot Receives: Behavioral: BeFree+Bot |
| Control | Active comparator | Text messages about quitting smoking Receives: Behavioral: BeFree |
What is being measured
The primary outcome is the main question the study is designed to answer.
Continuous abstinence
the longest continuous period (in days) that you did not smoke a cigarette
Measured: at 1 month follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2025
- Study startOct 2026 (estimated)
- Primary completion30 Mar 2027 (estimated)
- Study completion30 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Smoking CessationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- George Washington University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lorien Abroms, George Washington University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07079306
- Sponsor's protocol ID
- GWUniversity
- Status last verified
- Oct 2026
- First submitted
- 14 Jul 2025
- Last updated
- 14 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: It is a small pilot study